Acurx Pharmaceuticals Inc Dossier - Source-backed chat

Acurx Pharmaceuticals Inc

ACXPNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)-1.01

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.26Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $5.4M

Enterprise Value −$5.2M

Shares Outstanding 3.9M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Acurx Pharmaceuticals is a late-stage biopharmaceutical company positioned to disrupt the treatment paradigm for Clostridioides difficile infections (CDI) with its lead candidate, ibezapolstat. By targeting the DNA polymerase IIIC enzyme, ibezapolstat offers a unique Gram-Positive Selective Spectrum (GPSS) mechanism that treats acute infection while sparing the healthy gut microbiome. Phase 2 trials demonstrated an exceptional 96% clinical cure rate and 0% recurrence among cured patients. With final FDA and EMA agreements on Phase 3 trial designs and potential regulatory flexibility allowing a single pivotal trial for registration, Acurx has a highly asymmetric upside. However, the investment remains high-risk due to the company's ongoing going-concern risk and the critical need for substantial dilutive or non-dilutive financing to execute its Phase 3 program.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$17.00

High · most bullish analyst$31.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Acurx fails to secure the necessary financing to initiate Phase 3 trials, leading to severe dilution through equity lines or a halt in clinical development. The open-label rCDI pilot trial experiences enrollment delays or fails to replicate the strong Phase 2 efficacy and recurrence-free profile, invalidating the single-agent paradigm shift thesis.

Base CaseCentral scenario

Ibezapolstat successfully initiates its open-label pilot trial in recurrent CDI in H2 2026, showing positive preliminary safety and microbiome-sparing data. The company secures a strategic partnership or non-dilutive funding to launch its international Phase 3 trials. Regulatory alignment allows for an accelerated approval pathway under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD).

Bull CaseUpside scenario

The bull case for Acurx is anchored on its novel class of DNA polymerase IIIC inhibitors, led by ibezapolstat, which is Phase 3-ready for Clostridioides difficile Infection (CDI). Ibezapolstat has demonstrated a 96% clinical cure rate in Phase 2 trials, with unique microbiome-preserving properties that significantly reduce recurrence rates compared to standard-of-care vancomycin. Backed by FDA QIDP and Fast-Track designations, positive EMA scientific advice, and a robust patent estate extending to 2039/2042, successful Phase 3 trials and subsequent commercialization or strategic partnership could unlock substantial value in the multi-billion dollar antibiotic resistance market.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated GPSS mechanism of action that selectively targets pathogens while preserving the gut microbiome.
Outstanding Phase 2 clinical data showing a 96% cure rate and 0% recurrence in cured patients.
FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations, providing regulatory incentives and market exclusivity.
Potential to shift the treatment paradigm of recurrent CDI from a two-agent regimen to a single-agent therapy.

Key Investment Risks

Going-concern risk with a limited cash runway of $9.3 million as of March 31, 2026, relative to high Phase 3 development costs.
High dependence on a single clinical candidate (ibezapolstat) for near-to-mid-term valuation.
Potential for significant shareholder dilution from ongoing utilization of equity lines of credit and warrant exercises.

Thesis Invalidation Triggers

Failure to initiate the recurrent CDI open-label pilot trial in the second half of 2026.
Inability to secure sufficient capital or a strategic partner to fund Phase 3 clinical trials.
Any clinical trial data showing recurrence rates or safety profiles inferior to standard-of-care vancomycin or fidaxomicin.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.